M&A, People, Pharma, R&D

Hit by setbacks, Lundbeck’s Deborah Dunsire inks a $400M cannabinoid buyout, adding a discovery site

New Lundbeck CEO Deborah Dunsire is turning to M&A to build the pipeline.

Early Monday the Danish biotech reported that Dunsire had agreed to pay $250 million cash to snag San Diego-based Abide Therapeutics, where researchers have been working on a cannabinoid platform for new drugs to treat brain diseases. 

In addition to the cash, Lundbeck is reserving up to $150 million for milestones. And they’ll be keeping the San Diego base, designating it as a discovery center for Lundbeck.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->